Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Trial of the LSD1 Inhibitor SP-2577 in Patients With Relapsed or Refractory Ewing Sarcoma

Trial Profile

Phase 1 Trial of the LSD1 Inhibitor SP-2577 in Patients With Relapsed or Refractory Ewing Sarcoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Seclidemstat (Primary)
  • Indications Ewing's sarcoma
  • Focus Adverse reactions
  • Sponsors Salarius Pharmaceuticals
  • Most Recent Events

    • 28 Oct 2019 According to a Salarius Pharmaceuticals media release, the investment by Aspire plus non-dilutive funding from the Cancer Prevention Research Institute of Texas (CPRIT) and ongoing financial support from the National Pediatric Cancer Foundation will help for the early data readouts from this study.
    • 08 Oct 2019 According to a Salarius Pharmaceuticals media release, Memorial Sloan Kettering Cancer Center ( enrollment led by Paul A. Meyers) in New York City and Nationwide Childrens Hospital ( enrollment led by Bhuvana A. Setty ), in Columbus, have been added as clinical trial sites in this trial. Addition of these centers brings the total number of active clinical trial sites to eight.
    • 24 Sep 2019 According to a Salarius Pharmaceuticals media release, the Safety Review Committee has approved the advancement of this trial to the fourth level dosing (600 mg Seclidemstat twice-daily) cohort. Enrolment is ongoing in the 600 mg dose cohort.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top